The group is persevering with Granite, but funds might be hard to come by.

Moderna has also canned projects targeting KRAS and Ox40L/IL-23/IL-36γ.

Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.

The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.

As the dust settles on ASCO the weekend’s immediate winners and losers emerge.

Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.

When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.

Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.

A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.